Discussing RA: Comparative outcomes of JAK inhibition and TNF blockade vs dual JAK–ROCK targeting
The IMID Forum
- Published
- July 31, 2025
- Duration
- 13:24
- Summary source
- description
- Last updated
- Jun 21, 2026
Discusses Join Professor Iain McInnes as he discusses the top publications in the world of RA. This month, the…
Summary
Join Professor Iain McInnes as he discusses the top publications in the world of RA. This month, the conversation covered the ‘dual JAK and ROCK inhibition with CPL’116 in patients with RA with inadequate response to MTX’ and ‘the benefit–risk analysis of UPA versus adalimumab in patients with RA and higher or lower risk of cardiovascular disease’
Intelligent report
Sign in to read teasers, or upgrade to Research Pro to commission a new dossier for this episode. Learn more →
Show notes
Join Professor Iain McInnes as he discusses the top publications in the world of RA. This month, the conversation covered the ‘dual JAK and ROCK inhibition with CPL’116 in patients with RA with inadequate response to MTX’ and ‘the benefit–risk analysis of UPA versus adalimumab in patients with RA and higher or lower risk of cardiovascular disease’